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1075MP-165 Clopfdogrel Pretreatment Prior to Percutaneous 
Coronary Intervention Attenuates Periprocedural Rise 
of C-Reactive Protein 
9:24 a.m. 
Deeoak P. Vivekananthaq Deepak L. Bhatt, Derek P. Chew, Albert W. Ghan, David J. 
Molitemo, Stephen G. Ellis, Eric J. Topol, The Cleveland Clinic Foundation, Cleveland, 
OH, Flinders Medical Centre, South Australia, Australia 
Introduction: Pretreatment with clopidogrel prior to percutaneous coronary intervention 
(PCI) has been associated with reduced rates of death and myocardial infarction (Ml). 
Clopidogrel pretreatment has also been found to be most efficwous in patients with high 
baseline levels of C-reactive protein (CRP), suggesting an antI-inflammatory effect. How- 
ever, it is unknown whether clopidogrel pretreatment attenuates the rise in CRP after 
PCI. 
Methods: We followed 635 consecutive patients in our PCI registry from 2000.2002 who 
had both preprocedural and postprocedural (within 24 hours) levels of ultrasensitive CRP 
drawn. Clopidogrel pretreatment was left to the discretion of the treating physician. We 
determmed the association behveen clopidogrel pretreatment and change in CRP after 
PCI. 
Results: Besides aspirin, a total of 262 patients were pretreated with clopidogrel and 553 
patients received no clopidogrel pretreatment. Patients pretreated with clopidogrel were 
more likely to be diabetic, to be using statins, and to have an acute coronary syndrome 
on presentation. The median baseline levels of CRP were similar between pretreatment 
patients and patients who received no pretreatment, 0.39 mgldl and 0.36 mgldl (P=O.69), 
respectively. However, the mean rise in CRP after PC1 was significantly attenuated with 
clopidogrel pretreatment compared to the nb pretreatment group (O.l5mg/dl vs. 0.43 mg/ 
dl, P=O.O26). After controlling for clinical and angiographic factors with linear regression 
analysis, clopidogrel pretreatment significantly attenuated the rise in CRP 24 hours after 
PCI (regression coefficient: -0.30, 95% Cl [-0.60 ,-O.Ol], P=O.O4). 
Conclusion: Clopidogrel pretreatment prior to PCI is associated with a significant atten- 
uation in periprocedural rise of CRP. This study adds to the growing evidence of the anti- 
inflammatory effects of clopidogre’. Further study is needed to determine whether the 
attenuation in CRP rise after PCI is the primary mechanism for the reduction in subse- 
quent death and Ml associated with clopidogrel. 
9:36 a.m. 
1075MP-166 Cardioprotective Effect of Chronic Treatment With 
Statins Prior to Percutaneous Coronary Intervention 
Carla Auauadro, Mariella Manfredi, Silvia Saccaggl. Teresa Mustica, Cristina Cavalotb, 
Andrea Mortara, Giuseppe Specchia, Policlinico di Monza, Mona, MI, Italy 
Background: The presence of elevated level of Troponin I, an highly sensitive and spe- 
cific marker of cardiac damage, has a negative prognostic value after percutaneous COT- 
onary angioplasty (PCI). Statins seem to have many different actions beside the 
cholesterol levels lowering one, i.e. vasodilatation, antioxidant and anti-proliferative effect 
and, probably, they may exert a protective action on endothelial function. Aim of this 
study is to verify whether a chronic treatment with Statins could reduce cardiac damage 
after PCI. 
Methods: 164 patient (pts), who underwent PCI because of the presence of angina1 
symptoms or evidence of inducible myocardial ischemia, were divided into two groups 
according to the presence (Gl) or absence (G2) of statins in their therapy before PCI (for 
at least 3 months prior to the procedure): Gl included 66 pts and G2 96 pts Troponin I 
levels were evaluated 6-12-24 hours after the procedure. Troponin I was defined positive 
if its blood levels were greater than 0.1 ng/dl. 
Results: Unstable angina was present in 17% of Gl and 23% of G2 pts. Multivessel dis- 
ease was present in 56% of Gl and 57% of G2 pts. One-vessel-PC1 was performed in 
90% of Gl and 64% of G2 pts. Troponin values remained normal in 41% of Gl pts and 
22% of G2. Troponin I >= 1 .O ng/dl was present in 4.5% of Gl and 21% of G2 (p=O.OOl). 
Multivariate analysis confirmed the relationship between statins therapy and the varia- 
tions of Troponin levels after PCI (p=O.Ol) 
Conclusions: pts not treated with statins before PCI showed significantly more frequent 
abnormal Troponin I values after the procedure. These results suggest a possible protec- 
tive role of statlns against myocardial damage during PCI. 
9:46 a.m. 
1075MP-167 Restenosis Is Not Increased in Mild or Moderate 
Chronic Kidney Disease: Results From the PRESTO 
Trfal 
Patricia J. M. Best, Peter B. Berger. Jeffrey R. Grannett, Barry R. Davis, James T. 
Willerson, David R. Holmes, Jr., Mayo Clinic and Foundation, Rochester, MN 
Background: Patients with chronic kidney disease (CKD) have an increased mortality 
after percutaneous coronary intervention (PCI). Even mild CKD doubles one-year mortal- 
ity. Restenosis may contribute to the increased late mortality in these patients. In the 
CKD population, restenosis is significantly increased with balloon angioplasty alone. No 
studies have prospectively determined if restenosis is increased in CKD after PCI in the 
current stenting era. 
Methods: We analysed 11,167 patients from the Prevention of REStenosis with Tranilast 
and its Outcomes (PRESTO) trial and categorized them by estimated creatinine clear- 
ance (<60 mlimin [n=l,749], 60-69 ml/min (n=4,054], >69 ml/min [n=5,364]) using the 
Cockroft-Gault formula. Chl-squared tests were used to investigate the association 
between the creatinine clearance group and death or myocardlal infarction or target ves- 
sel revascularization and a generalized estimating equation model was used to deter- 
mine the interaction with restenosis. 
Results: Pattents in the lowest creatinine clearance group were older, had a greater pro- 
portlon of women, and had more diabetes. At 30 days, there was no difference in 
adverse events between those in the lowest, mlddle, and highest creatinine clearance 
groups in terms of myocardial infarction (1% vs. O%, vs. O%, p=O.33), death (0%. vs. O%, 
vs. O%, p=O.O6), or target vessel revascularization (l%, vs. l%, vs. l%, ~~0.28) respec- 
tively. At 9 months, mortality was higher in the lowest creatinine clearance group (2% vs. 
1% vs. l%, p <O.OOl), but myocardial infarction and target vessel revascularization were 
not different. In patients undergoing protocol follow-up angiography (n=2,556), restenosis 
was not increased with CKD (32% vs. 32% vs. 37%. p=O.l3). 
Conclusion: Mortality at 9 months is mildly increased in patients with mild or moderate 
CKD after PCI. Restenosis is not increased in CKD and does not account for this 
increased mortality. 
10:00 a.m. 
1075MP-168 The Use of Ilb/llla Inhibitors in Patients With In-ltent 
Restenosis Treated With lntracoronary Gamma 
Radiation: Results From the Clinical Trial INTEGRILIN 
WRIST 
Ron Waksman. Edouard F. Cheneau, Robert Lew, August0 Plchard, Lowell F. Satler, 
William 0. Suddath, Laurent Leborgne, Regina Dieble, Rebecca Torguson, Maria 
Medina, Afework GebreEyesus, Joseph Lindsay. Washington Hospital Center, 
Washington, DC 
Background: lntracoronary Radiation Therapy (IRT) reduces the recurrence of in-stent 
restenosis (ISR). The use of Ilb/llla inhibitors in conventional PCI reported to reduce CK 
release and cardiac events. This study examined the impact llblllla inhibitors as adjunct 
therapy to IRT for patients with ISR. 
Methods: INTEGRILIN WRIST was designed as a randomized 1:l open label study for 
300 patients with diffuse ISR in native coronaries and vein grafts with lesions ~60 mm, 
who underwent PCI (re-stenting in 43%) followed by IRT utilizing k-192 emitter dose of 
15 Gy at 2 mm. In the study 150 patients assigned to Eftibatide (Integrilin) with double 
bolus of 160 mcglkg and 2.0 mcglkg-min infusion xl6 hours + heparln 60 U/kg bolus 
(ACT 200-300 set) and 150 patients to heparin only. Patients were discharged with clopi- 
dogrel 75 mg/QD for 6 months. The primary objectives of this study were clinical com- 
posite endpoints, CKMB, MI, death and target lesion revascularization. 
Results: Baseline clmical, angiographic, and procedural characteristics were similar fo[ 
patients with and without Eftibatide. The use of Eftibatide was not associated with an 
increase in bleeding. Clinical composite endpoints at 30 days were similar between the 
patients treated with and without Eftibatide (Table). 
Conclusion: The use of Eftibatide as adjunct therapy for patients with ISR that are 
treated with IRT does not impact the clinical outcome at 30 days. The 9 month clinical 
and angiographic results will be ready at presentation. 
In hospital and 30 days follow-up 
Eftibatide Control P 
TVR MACE 1.4 2.6 0.62 
Q-MI 1.4 2.1 0.62 
non Q-MI 19.9 16.4 0.76 
CK-MB>3 15.4 19.5 0.37 
Vascular Complications 4.6 1.4 0.10 
Bleeding 7.5 4.3 0.24 
IO:12 a.m. 
1075MP-169 Oral Sirolimus to Prevent Restenosis After Stenting De 
Novo Coronary Lesions 
Costantino R. Costantini, Daniel Zanuttini. Sergio Tarbine, Rubens Dalwich, Jose L. 
Lazarte, Costantino 0. Costantini, Mario Maranhao, Manuel Andrade, Maria R. Oliveira, 
Luis Sabattini, Gilson Yared, Marco Bubna, Marco Medeiro. Laura Rubbini, Marcel0 
Freitas, Clinica Cardiologyca C Costantini, Curitiba, Brazil 
Background: Sirolimus drug-eluted stem (DES) suppress intimal hyperplasia in pts with 
denovo (DN) coronary lesions. We conducted a prospectwe clinical study to assess the 
safety and efficacy of oral Sirolimus for prevention of restenosis after DN lesions Stem 
implantation 
Methods: From 1 l/2001 to 6/2002, 22 DN coronary lesions underwent stent PCI in 20 
pts. Treatment with oral sirolimus was started with a loading dose of 6mg before PCI fol- 
lowed by Pmglday for 14 days. Before PCI. at 10 days, 1 and 6 months pts were clinically 
assessed and serum electrolytes, lipid profile, renal panel, and complete blood count 
were measured. Anglographic and IVUS volumetric analysis were performed at baseline 
and at 4 months follow-up. 
Results: The mean age was 6427 years, 75% were male and 20% had Dhi. Baseline 
mean reference diameter was 3.16 * 0.35mm, MLD was 1.0&0.24 and DS 65%. 22 BX 
Velocity (Cordis) stents were implanted guided by IVUS with a mean pressure of 
17.2r2.latm. Angiographic success was 100% with a final MLD of 3.lkO.6 and DS% of 
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19%. To date, follow-up angiographic and IVUS volumetric analysis was performed in 17 
lesions and the results are showed in the table bellow. There were no cardiac Or drug- 
related adverse clinical events. 
PROXIMAL STENT DISTAL 
EDGE EDGE 
MLD (mm) 2.74*0.79 2.61*0.68 2.84*0.48 
Late Loss (mm) 0.47 0,52 0,19 
Restenosis Rate % (>50%DS) 5.9 5.9 0 
Lumen Volume (mm3) 33.3+11.6 115.1*46.9 35.6t8.7 
lntimal Hyperplasia Volume (mm3) 6.7 15.5 1.4 
lntimal Hyperplasia (% of volume) 16.7 11.8 3,7 
Hyperplasia Index (mmYmm) 1,3 0,97 0,2 
Conclusions: Oral Sirolimus treatment during 14 days showed to be safe without car- 
diac or drug-related adverse events. Angiographic and IVUS volumetric analysis suggest 
that adjunct oral Sirolimus decrease neointimal hyperplasia after Stem implantation in 
denovo coronary lesions 
lo:24 a.m. 
1075MP-170 Bivalirudin Reduces lschemic and Hemorrhagic 
Complications of Percutaneous Coronary Intervention: 
Pooled Data From 10 Prospective Studies in 6,134 
Patients 
Frederick Feit, John A. Bittl, A. Michael Lincoff, Derek P. Chew, Neal S. Kleiman, Lars 
Wallentin. Harvey D. White, John Omiston, Richard Robson, Philip E. Aylward, Michael 
J. Attubato, New York University School of Medicine, New York, NY, The Cleveland 
Clinic Foundation, Cleveland, OH 
Background: Bivalirudin is a thrombin-specific anticoagulant approved for use in angio- 
plasty. Recent studies have evaluated the use of bivalirudin with GP Ilb/llla inhibitors and 
stents. We combined the entire reported clinical trial experience for bivalirudin vs. hep- 
arin in percutaneous coronary intetventlon (PCI). 
Methods: Ten prospective PCI studies performed between 1993 and 2001 were 
included in the analvs~s. A Sinale data set was built usina common data fields and 
descriptions of vanables. Bivalirudin and heparin were given at a range of doses consis- 
tent with the standard of care at the time. Thienoovridines were aiven in 8 studies: GPllb/ 
I  
llla inhibitors in 6 studies. Myocardlal infarction (Ml) was generally defined as CK-MB > 
3x normal and hemorrhage as a > 3g/dl decrease in hemoglobin. 
Results: A total of 6,134 patients, median age 63 yrs, 70% male, were treated with biva- 
lirudin (n=3,277) or heparin (“~2,857). The results for the ischemic (death, MI. target ves- 
sel revascularization (TVR)) and hemorrhagic endpoints within seven days are shown in 
the table. 
Conclusions: In this analysis of IO prospective PCI trials, bivalirudin reduced the triple 
lschemic endpoint of death, MI, TVR by 24% (p=O.O03) and reduced hemorrhage by 63% 
(p<O.OOOl). Thus, bivalirudin is superior to heparin in preventing both ischemic and hem- 
orrhaglc complications in a broad population of patients undergoing PCI. 
All PC1 Trials nz6.134 
Bivalirudin (n=3,277) Heparin (n=2,857) 
n (%) n (%) 
Any event 241 (7.4) 372 (13.0) 
Death/MI/TVR 186 (5.7) 215 (7.5) 
Death/Ml 113 (3.4) 127 (4.4) 
Death 7 (0.2) 8 (0.3) 
Ml 109 (3.3) 124 (4.3) 
NR 107 (3.3) 137 (4.8) 
Hemorrhage 91 (2.8) 217 (7.6) 
p-value 
<0.0001 
0.003 
0.045 
0.599 
0.038 
0.002 
<0.0001 
lo:36 a.m. 
1075MP-171 Excessive Body Weight Does Not Increase the Risk of 
Complications Following Percutaneous Coronary 
Interventions 
Abel E. Morevra, Ajay K. Agarwala, Kenneth Khaw, Natalie Socha, Alan C. Wilson, 
UMDNJ-Roben Wood Johnson Medical School, New Brunswick, NJ 
Background: Excessive body weight (BMI) has been reported as a risk factor for compli- 
cations following percutaneous coronary interventions (PCI). However, recent significant 
technological advances in PCI have prompted a re-examination of this association to 
study the association of exceswe BMI with increased complications of PCI. 
Methods: A university hospital database of 9,537 consecutive patients undergoing PCI 
was analyzed. The International Obesity Task Force classifwtion was used. 
Results: There were no significant differences in the rates of success, emergency 
bypass surgery (CABG), transfusion, or bleeding complications between the BMI 
classes. Healthy weight patients had a higher In-hospital death rate (1.8%, p=O.O03) 
compared to the other BMI classes. After adjusting for demographic and procedural vari- 
ables with multivariate analysis, BMI had no independent association with PCI complaa- 
tions. 
Conclusion: In contrast with previous reports, excessive BMI (>35) was not found to be 
a risk factor for death or major complications of PCI. Although bleeding complications 
were higher among patients with higher BMI, the incidence rate was lower than previ- 
ously reported. We conclude that these favorable results may be due to new technolo- 
gies and improved anticoagulation approaches. 
PC1 Outcomes by BMI Class 
Healthy Overweig Obese 1 Obese Obese P 
18.5to ht 30to 2 3 Value 
<25 25 to ~30 <35 35 > 40 
to<40 
N 2,259 4,188 2,049 739 302 - 
Success Rate, % 96 96 96 96 95 NS 
Death, % 1.8 1.0 0.7 0.8 0.7 0.003 
Emergency CABG, % 1.1 0.7 1.2 0.8 1.5 NS 
Bleeding Complication, 1.9 0.8 1.4 1.6 2.6 NS 
% 
10:4B a.m. 
1075MP-172 Kinetics of Intravenously Administered Dalteparin 
Chad C. Schoolev Jerry H. Gilbert, Mary Harlan, Arthur Bracey, Stephanie Coulter, 
James M. Wilson, Baylor College of Medicine, Houston, TX, Texas Heart Institute, 
Houston, TX 
Background: Outcomes using low molecular weight heparins for unstable angina and 
myccardial infarction have stimulated interest in their use during percutaneous coronary 
intewention (PCI). To define drug-dose response and clearance, we measured the anti- 
Xa activity at fixed time points after IV bolus dosing of dalteparin. 
Methods:20 medication-free volunteers (10 male, 10 female) with normal renal function 
were treated at 2 week intervals with each of 3 dalteparin doses (40, 60, and 80 IU/kg). 
Using a peripheral IV catheter, anti-Xa and anti-lla activities were measured at baseline, 
5, 15. 30, 45, 60, 240. and 480 minutes after the IV administration of dalteparin. Single 
exponential modeling was used to calculate the effective half-life (r1,28) for indivtduals 
and examine the effect of dose. The simplified MDRD formula was used to calculate 
glomerular filtration rate (GFR). 
FteeuI1B: Subjects had a mean age of 35 *4 years and mean weight of 77 +lOkg with 
GFR of 92*15 ml/min. The peak anti-Xa and anti-lla activities, T,,,. of anti-Xa activity 
after a single administration, terminal half-life of anti-Xa activity, and clearance values 
are listed below. The volume of distribution (Vd) was 41 210 ml/kg. The TIiPe was similar 
for 40 and 60 IU/kg. but was longer after a dose of 80 IUikg (p=O.O09). There was no cor- 
relation between T,i2. and GFR. 
Conclusiorr The pharmacokinetics of dalteparin I” normal individuals are described. 
These results will assist in the design of trials of dalteparin anticoagulation during PCI. 
Anti-Xa Activity Effective Tl/Z Terminal Tl12 Clearance 
(U/ml) (min) (min) (mllmin) 
40 1u/kg 1.07 64 107 25 
60 IUlkg 1.53 65 103 23 
80 IU/kg 1.83 82 128 29 
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1076-l 84 Left Ventricular Function in the Stent or Surgery Trial 
One Year After Randomization to Coronary Artery 
Bypass Graft Surgery or Stent Percutaneous Coronary 
Intervention 
Georae Koutroulis Marina Flitsou, Jean Booth, Tim Clayton, Rod H. Stables, Fiona 
Nugara, Petros Nihoyannopoulos. Hammersmith Hospital, NHLI, ICSM. London, United 
Kingdom, Royal Brompton Hospital, London, United Kingdom 
Background: In the Stem or Surgery study, we prospectively randomlsed 500 pattents to 
coronary artery bypass graft surgery (CABG) and 488 patients to stenting percutaneous 
coronary intervention (PCI), for optlmal revascularisation. We hypothesised that left ven- 
tricular (LV) function at 1 year post procedure wll be the same, regardless the initial 
treatment allocation. 
Methods: Global LV function was assessed by eJection fraction (EF, biplane modified 
Simpson’s rule), and reglonal LV function by the wall motion score index (WMSI, Ameri- 
can Society of Echocardiography), using echocardiography. Echocardiographic studies 
were analysed blindly at a core laboratory Primary outcome was a comparison of WMSI 
